1. Home
  2. TVTX vs CORT Comparison

TVTX vs CORT Comparison

Compare TVTX & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

HOLD

Current Price

$40.41

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Logo Corcept Therapeutics Incorporated

CORT

Corcept Therapeutics Incorporated

HOLD

Current Price

$46.42

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TVTX
CORT
Founded
N/A
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
3.7B
IPO Year
2013
2001

Fundamental Metrics

Financial Performance
Metric
TVTX
CORT
Price
$40.41
$46.42
Analyst Decision
Strong Buy
Buy
Analyst Count
14
5
Target Price
$40.46
$96.50
AVG Volume (30 Days)
2.2M
1.8M
Earning Date
05-07-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
92.89
N/A
EPS
N/A
0.82
Revenue
N/A
$761,407,000.00
Revenue This Year
$43.88
$26.08
Revenue Next Year
$33.16
$31.04
P/E Ratio
N/A
$53.61
Revenue Growth
N/A
12.79
52 Week Low
$13.88
$28.66
52 Week High
$43.31
$91.00

Technical Indicators

Market Signals
Indicator
TVTX
CORT
Relative Strength Index (RSI) 69.56 72.72
Support Level $32.62 $32.95
Resistance Level $41.44 $47.06
Average True Range (ATR) 2.17 1.74
MACD 1.26 0.56
Stochastic Oscillator 82.25 99.12

Price Performance

Historical Comparison
TVTX
CORT

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.

Share on Social Networks: